NMD Pharma Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
64
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$79.8M
- Investors
-
8
NMD Pharma General Information
Description
Operator of a clinical-stage biotech company intended to design drugs and therapeutics for the treatment of neuromuscular disorders. The company's drugs help to strengthen neuromuscular transmission and muscle function in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical needs, enabling improvement in the quality of life and survival of patients with neuromuscular disorders.
Contact Information
Website
www.nmdpharma.comCorporate Office
- Palle Juul-Jensens Boulevard 82
- Aarhus N
- 8200 Aarhus
- Denmark
Corporate Office
- Palle Juul-Jensens Boulevard 82
- Aarhus N
- 8200 Aarhus
- Denmark
NMD Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series B) | 15-Nov-2023 | $79.8M | Completed | Clinical Trials - Phase 2 | ||
| 7. Later Stage VC (Series A2) | 15-Feb-2022 | Completed | Clinical Trials - Phase 2 | |||
| 6. Grant | 01-Jan-2022 | Completed | Clinical Trials - Phase 2 | |||
| 5. Grant | 30-Nov-2020 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series A) | 23-Mar-2018 | Completed | Clinical Trials - General | |||
| 3. Seed Round | 13-Jun-2016 | Completed | Clinical Trials - General | |||
| 2. Seed Round | $3.79M | $3.79M | Completed | Startup | ||
| 1. University Spin-Out | 01-Jan-2015 | Completed | Startup |
NMD Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference | ||||||||
| Preference | 156,794 | $23.7 | $23.7 | 1x | $23.7 | 3.64% | ||
| Preference | 125,000 | $22.79 | $22.79 | 1x | $22.79 | 2.9% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
NMD Pharma Comparisons
Industry
Financing
Details
NMD Pharma Competitors (58)
One of NMD Pharma’s 58 competitors is Baliopharm, a Venture Capital-Backed company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Baliopharm | Venture Capital-Backed | Basel, Switzerland | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| CuraSen | Venture Capital-Backed | San Carlos, CA | ||||
| Neurogene | Formerly VC-backed | New York, NY |
NMD Pharma Patents
NMD Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026190100-A1 | A chloride ion channel 1 inhibitor for use in disease modifying effects in the treatment of a neuromuscular disease | Pending | 14-Mar-2025 | ||
| WO-2025196186-A1 | Compounds for the treatment of neuromuscular disorders | Pending | 20-Mar-2024 | ||
| WO-2025196206-A1 | Compounds for the treatment of neuromuscular disorders | Pending | 20-Mar-2024 | ||
| AU-2024311729-A1 | Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases | Pending | 20-Jun-2023 | ||
| EP-4731200-A1 | Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases | Pending | 20-Jun-2023 | A61K31/192 |
NMD Pharma Signals
NMD Pharma Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Jeito | Growth/Expansion | Minority | ||
| INCUBA | Accelerator/Incubator | |||
| Innovationsfonden | Accelerator/Incubator | |||
| Inkef | Venture Capital | Minority | ||
| Roche Venture Fund | Corporate Venture Capital | Minority |
NMD Pharma FAQs
-
When was NMD Pharma founded?
NMD Pharma was founded in 2015.
-
Where is NMD Pharma headquartered?
NMD Pharma is headquartered in Aarhus, Denmark.
-
What is the size of NMD Pharma?
NMD Pharma has 64 total employees.
-
What industry is NMD Pharma in?
NMD Pharma’s primary industry is Drug Discovery.
-
Is NMD Pharma a private or public company?
NMD Pharma is a Private company.
-
What is NMD Pharma’s current revenue?
The current revenue for NMD Pharma is .
-
How much funding has NMD Pharma raised over time?
NMD Pharma has raised $173M.
-
Who are NMD Pharma’s investors?
Jeito, INCUBA, Innovationsfonden, Inkef, and Roche Venture Fund are 5 of 8 investors who have invested in NMD Pharma.
-
Who are NMD Pharma’s competitors?
Baliopharm, NGM Biopharmaceuticals, Neurona Therapeutics, CuraSen, and Neurogene are some of the 58 competitors of NMD Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process